Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Core Insights - Arch Biopartners Inc. has received provincial ethics approval for its Phase II trial of LSALT peptide aimed at preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI) [1][3] - The trial will recruit a total of 240 patients across multiple sites, including Toronto General Hospital, St. Michael’s Hospital, University of Calgary Hospital, and five clinical sites in Turkey [2][3][4] - The primary objective of the trial is to assess the percentage of subjects experiencing acute kidney injury within seven days post cardiac surgery, following KDIGO criteria [4] Company Developments - Arch Biopartners has entered a one-year marketing and consulting contract with Outside The Box Capital Inc. to enhance awareness of the company’s news [10] - The company will pay $25,000 per month and grant 150,000 stock options with a strike price of $2.00 per share as part of the contract [11] - Arch Biopartners is focused on developing drugs targeting the dipeptidase-1 (DPEP1) inflammation pathway, with LSALT peptide being its lead candidate for preventing kidney injury [12] Clinical Context - CS-AKI is a common complication following on-pump cardiac surgeries, with a prevalence rate of up to 30%, leading to increased morbidity and mortality [8] - LSALT peptide aims to address the unmet medical need for therapeutic treatments to prevent AKI in patients undergoing cardiac surgery [6][12] - The drug has shown promise in pre-clinical models for preventing ischemia-reperfusion injury to the kidneys, providing a scientific basis for its use in the ongoing trial [7]